Cite
An oncogenic CTNNB1 mutation is predictive of post-operative recurrence-free survival in an EGFR-mutant lung adenocarcinoma.
MLA
Kim, Yeseul, et al. “An Oncogenic CTNNB1 Mutation Is Predictive of Post-Operative Recurrence-Free Survival in an EGFR-Mutant Lung Adenocarcinoma.” PLoS ONE, vol. 17, no. 6, June 2023, pp. 1–16. EBSCOhost, https://doi.org/10.1371/journal.pone.0287256.
APA
Kim, Y., Ahn, B., Yoon, S., Lee, G., Kim, D., Chun, S.-M., Kim, H.-R., Jang, S. J., & Hwang, H. S. (2023). An oncogenic CTNNB1 mutation is predictive of post-operative recurrence-free survival in an EGFR-mutant lung adenocarcinoma. PLoS ONE, 17(6), 1–16. https://doi.org/10.1371/journal.pone.0287256
Chicago
Kim, Yeseul, Bokyung Ahn, Shinkyo Yoon, Goeun Lee, Deokhoon Kim, Sung-Min Chun, Hyeong-Ryul Kim, Se Jin Jang, and Hee Sang Hwang. 2023. “An Oncogenic CTNNB1 Mutation Is Predictive of Post-Operative Recurrence-Free Survival in an EGFR-Mutant Lung Adenocarcinoma.” PLoS ONE 17 (6): 1–16. doi:10.1371/journal.pone.0287256.